ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.
[en] BACKGROUND: Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to improve oxalate excretion, or reduce oxalate generation, to prevent kidney function deterioration. Oxalobacter formigenes is an oxalate metabolizing bacterium. This Phase III, double-blind, placebo-controlled randomized trial investigated the effectiveness of orally administered Oxabact™, a lyophilized O. formigenes formulation, at reducing plasma oxalate levels in patients suffering from PH. METHODS: Subjects (≥ 2 years of age) with a diagnosis of PH and maintained but suboptimal kidney function (mean estimated glomerular filtration rate at baseline < 90 mL/min/1.73 m(2)) were eligible to participate. Subjects were randomized to receive Oxabact or placebo twice daily for 52 weeks. Change from baseline in plasma oxalate concentration at Week 52 was the primary study endpoint. RESULTS: Forty-three subjects were screened, 25 were recruited and one was discontinued. At Week 52, O. formigenes was established in the gut of subjects receiving Oxabact. Despite decreasing plasma oxalate level in subjects treated with Oxabact, and stable/increased levels with placebo, there was no significant difference between groups in the primary outcome (Least Squares mean estimate of treatment difference was - 3.80 μmol/L; 95% CI: - 7.83, 0.23; p-value = 0.064). Kidney function remained stable in both treatments. CONCLUSIONS: Oxabact treatment may have stabilized/reduced plasma oxalate versus a rise with placebo, but the difference over 12 months was not statistically significant (p = 0.06). A subtle effect observed with Oxabact suggests that O. formigenes may aid in preventing kidney stones. A higher resolution version of the Graphical abstract is available as Supplementary information.
Collard, Laure ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie ; Centre Hospitalier Umniversitaire de Liege, Liege, Belgium.
ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.
Publication date :
February 2023
Journal title :
Pediatric Nephrology
ISSN :
0931-041X
eISSN :
1432-198X
Publisher :
Springer International, Berlin, United States - Delaware
Oxalosis & Hyperoxaluria Foundation (2019) https://www.ohf.org. Accessed 24 September 2021
Cochat P, Rumsby G (2013) Primary hyperoxaluria N Eng J Med 369:649–658. 10.1056/NEJMra1301564 DOI: 10.1056/NEJMra1301564
Milliner DS, Harris PC, Cogal AG, Lieske JC (2002) Primary hyperoxaluria type 1. 2002 Jun 19 [Updated 2017 Nov 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1283/
Hoppe B, Beck BB, Milliner DS (2009) The primary hyperoxalurias. Kidney Int 75:1264–1271. 10.1038/ki.2009.32 DOI: 10.1038/ki.2009.32
Khan SR (2010) Nephrocalcinosis in animal models with and without stones. Urol Res 38:429–438. 10.1007/s00240-010-0303-4 DOI: 10.1007/s00240-010-0303-4
Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ, Flavell RA, Aronson PS (2013) NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 84:895–901. 10.1038/ki.2013.207 DOI: 10.1038/ki.2013.207
Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ (2013) Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 123:236–246. 10.1172/JCI63679 DOI: 10.1172/JCI63679
Milliner DS, Cochat P, Hulton SA, Harambat J, Banos A, Dehmel B, Lindner E (2021) Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol 36:1785–1793. 10.1007/s00467-020-04894-9 DOI: 10.1007/s00467-020-04894-9
Perinpam M, Enders FT, Mara KC, Vaughan LE, Mehta RA, Voskoboev N, Milliner DS, Lieske JC (2017) Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria enteric hyperoxaluria and urinary stone disease. Clin Biochem 50:1014–1019 DOI: 10.1016/j.clinbiochem.2017.07.017
Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, Lieske JC, Milliner DS (2010) Cardiac abnormalities in primary hyperoxaluria. Circ J 74:2403–2409. 10.1253/circj.CJ-10-0107 DOI: 10.1253/circj.CJ-10-0107
Bruel A, Bacchetta J, Ginhoux T, Rodier-Bonifas C, Sellier-Leclerc AL, Fromy B, Cochat P, Sigaudo-Roussel D, Dubourg L (2019) Skin microvascular dysfunction as an early cardiovascular marker in primary hyperoxaluria type I. Pediatr Nephrol 34:319–327. 10.1007/s00467-018-4081-5 DOI: 10.1007/s00467-018-4081-5
Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U (2021) Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study. Nephrol Dial Transplant 36:1464–1473. 10.1093/ndt/gfaa135 DOI: 10.1093/ndt/gfaa135
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC, ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216–1226. 10.1056/NEJMoa2021712 DOI: 10.1056/NEJMoa2021712
Hatch M, Freel RW (2013) A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. Urolithiasis 41:379–384. 10.1007/s00240-013-0601-8 DOI: 10.1007/s00240-013-0601-8
Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW (2006) Oxalobacter sp. reduces urinary oxalate excretion promoting enteric oxalate excretion. Kidney Int 69:1–8. 10.1038/sj.ki.5000162 DOI: 10.1038/sj.ki.5000162
Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW (2011) Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 300:G461–G469. 10.1152/ajpgi.00434.2010 DOI: 10.1152/ajpgi.00434.2010
Knauf F, Lo N, Jiang Z, Robertson WG, Van Itallie CM, Anderson JM, Aronson PS (2011) Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion. J Am Soc Nephrol 22:2247–2255. 10.1681/ASN.2011040433 DOI: 10.1681/ASN.2011040433
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H (2006) Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 70:1305–1311. 10.1038/sj.ki.5001707 DOI: 10.1038/sj.ki.5001707
Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D (2011) Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26:3609–3615. 10.1093/ndt/gfr107 DOI: 10.1093/ndt/gfr107
Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC (2020) Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. Int J Mol Sci 21:3608. 10.3390/ijms21103608 DOI: 10.3390/ijms21103608
Schwartz GJ, Muñoz A, Schneider MF, Robert MH, Frederick K, Bradley WA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637. 10.1681/ASN.2008030287 DOI: 10.1681/ASN.2008030287
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med. 2011 Sep 20;155:408]. Ann Intern Med 150:604–612. 10.7326/0003-4819-150-9-200905050-00006 DOI: 10.7326/0003-4819-150-9-200905050-00006
Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS, Investigators of rare kidney stone consortium (2016) Predictors of incident ESRD among subjects with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126. 10.2215/CJN.02810315 DOI: 10.2215/CJN.02810315
Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG (2011) Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol 186:135–139. 10.1016/j.juro.2011.03.006 DOI: 10.1016/j.juro.2011.03.006
Boyce AM, Shawker TH, Hill SC, Choyke PL, Hill MC, James R, Yovetich NA, Collins MT, Gafni RI (2013) Ultrasound is superior to computed tomography for assessment of medullary nephrocalcinosis in hypoparathyroidism. J Clin Endocrin Metab 98:989–994. 10.1210/jc.2012-2747 DOI: 10.1210/jc.2012-2747
Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van’t Hoff W, Moochhala SH, Deschênes G, Lindner E, Sjögren A, Cochat P (2017) A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr Nephrol 32:781–790. 10.1007/s00467-016-3553-8 DOI: 10.1007/s00467-016-3553-8
Milliner D, Hoppe B, Groothoff J (2018) A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis 46:313–323. 10.1007/s00240-017-0998-6 DOI: 10.1007/s00240-017-0998-6
Sivaguru M, Saw JJ, Williams JC Jr, Lieske JC, Krambeck AE, Romero MF, Chia N, Schwaderer AL, Alcalde RE, Bruce WJ, Wildman DE, Fried GA, Werth CJ, Reeder RJ, Yau PM, Sanford RA, Fouke BW (2018) Geobiology reveals how human kidney stones dissolve in vivo. Sci Rep 8:13731. 10.1038/s41598-018-31890-9 DOI: 10.1038/s41598-018-31890-9
Harris AH, Freel RW, Hatch M (2004) Serum oxalate in human beings and rats as determined with the use of ion chromatography. J Lab Clin Med 144:45–52 DOI: 10.1016/j.lab.2004.04.008
Clifford-Mobley O, Sjogren A, Lindner E, Rumsby G (2016) Urine oxalate biological variation in patients with primary hyperoxaluria. Urolithiasis 44:333–337. 10.1007/s00240-016-0860-2 DOI: 10.1007/s00240-016-0860-2
Verhulst A, Dehmel B, Lindner E, Akerman ME, D’Haese PC (2022) Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition. Urolithiasis. 10.1007/s00240-022-01310-9 DOI: 10.1007/s00240-022-01310-9
